Market Closed -
Nasdaq
04:00:00 2024-06-07 pm EDT
5-day change
1st Jan Change
21.88
USD
-1.35%
+0.88%
-8.80%
Sales 2024 *
1.88B
Sales 2025 *
2.06B
Capitalization
6.37B
Net income 2024 *
342M
Net income 2025 *
444M
EV / Sales 2024 *
2.8
x
Net cash position
2024
*
1.12B
Net cash position
2025
*
1.67B
EV / Sales 2025 *
2.28
x P/E ratio 2024 *
19.4
x
P/E ratio 2025 *
14.9
x
Employees
1,310
Yield 2024 *
-
Yield 2025 *
-
Free-Float
97.81%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Transcript : Exelixis, Inc. Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 03:20 PM
Jun. 04
Exelixis Insider Bought Shares Worth $8,733,955, According to a Recent SEC Filing
May. 31
MT
Exelixis Settles Cabometyx Patent Litigation with Cipla
May. 20
MT
Transcript : Exelixis, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 02:35 PM
May. 14
Transcript : Exelixis, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 11:20 AM
May. 14
Transcript : Exelixis, Inc. Presents at The Citizens JMP Life Sciences Conference, May-14-2024 09:30 AM
May. 14
Stephens Initiates Exelixis With Equalweight Rating, $23 Price Target
May. 14
MT
Exelixis Files Patent Complaint Against Cipla's Cancer Treatment
May. 10
DJ
RBC Trims Exelixis' Price Target to $27 From $28, Outperform Rating Kept
May. 01
MT
Exelixis Q1 Non-GAAP Earnings, Revenue Rise; 2024 Revenue Guidance Maintained -- Shares Fall After Hours
Apr. 30
MT
Transcript : Exelixis, Inc., Q1 2024 Earnings Call, Apr 30, 2024
Apr. 30
Exelixis Guides For 2024 Revenue of $1.825-$1.925 Billion, vs CIQ Analyst Consensus of $1.91 Billion
Apr. 30
MT
Earnings Flash (EXEL) EXELIXIS Reports Q1 Revenue $425.2M, vs. Street Est of $460.5M
Apr. 30
MT
Earnings Flash (EXEL) EXELIXIS Reports Q1 EPS $0.17, vs. Street Est of $0.29
Apr. 30
MT
Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on January 8, 2024.
Apr. 30
CI
More news
Ipsen s'apprête à présenter de nouvelles données positives sur le Cabometyx
Jan. 23
En Direct des Marchés : TotalEnergies, Unibail, Saint-Gobain, Ipsen, Abivax, Amazon, Ryanair...
23-08-21
Les valeurs à suivre aujourd'hui à la Bourse de Paris - Lundi 21 août 2023
23-08-21
Ipsen : Exelixis et Ipsen annoncent les résultats positifs de l’'essai pivot de Phase III CONTACT-02
23-08-21
EN DIRECTO DESDE LOS MERCADOS: Aena, TotalEnergies, FedEx, Volkswagen, Adobe, Ipsen, Abivax, Amazon, Ryanair...
23-08-21
More news 1 day -1.35%
1 week +0.88%
Current month +0.88%
1 month +0.55%
3 months -1.49%
6 months -0.55%
Current year -8.80%
More quotes
Managers
Title Age Since
Chief Executive Officer
63
00-01-31
Director of Finance/CFO
56
15-07-14
Chief Tech/Sci/R&D Officer
57
23-08-22
Members of the board
Title Age Since
Director/Board Member
68
04-01-31
Director/Board Member
79
04-07-31
Founder
75
94-11-14
More insiders
Date
Price
Change
Volume
24-06-07
21.88
-1.35%
1,303,478
24-06-06
22.18
+1.00%
1,393,084
24-06-05
21.96
+1.01%
1,384,531
24-06-04
21.74
-0.87%
1,506,416
24-06-03
21.93
+1.11%
2,025,173
Delayed Quote
Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotes
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
More about the company
Last Close Price
21.88
USD
Average target price
26.59
USD
Spread / Average Target
+21.52%
Consensus
1st Jan change
Capi.
-8.80% 6.37B +18.72% 125B +14.19% 108B -4.93% 24.21B +1.57% 22.78B -10.88% 17.96B -41.74% 16.43B -13.31% 16.37B +2.44% 13.58B +27.89% 11.66B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1